Key findings

  • 200mg per dayoral mifepristone, the dose most patients took; a few were treated with 300mg per day
  • 57.6% vs 27%survival of A/J mice with spontaneous lung cancer given mifepristone versus controls
  • 11.6 vs 57.6mean sick days, judged by a blinded observer, in mifepristone-treated mice versus controls
  • 66.7%overall 5-year survival reported in a 6-patient review of terminal lung cancer patients treated with mifepristone

Abstract

Background
There is evidence that malignant tumors proliferate and metastasize at least in part by secreting immunomodulatory proteins similar to the fetus. One of them is called the progesterone-induced blocking factor. The secretion of progesterone induced blocking factor requires activation of membrane progesterone receptors not nuclear receptors.
Observation
Treating mice and humans with the PR modulator mifepristone may suppress the production of PIBF which is the best hypothesis to explain why patients with a variety of different very advanced cancers frequently have a considerable extension of life- (sometimes over 5 years) despite their terminal state. Interestingly, the large majority of these patients gain marked palliative benefits, such as pain relief and renewed energy, within a short period of time even before there is evidence of tumor regression. Generally, computed tomography scans show partial remission or stable disease but rarely show complete remission. However, even if a given primary or metastatic lesion begins to increase in size, continued palliative benefits and life extension will usually continue. Stopping the drug for even 2 weeks will usually lead to death in a short period of time related to rapid proliferation of the cancer once again. One caveat, if used at an earlier stage of cancer, it seems to be best for cancers devoid of the nuclear progesterone receptor since the nuclear progesterone receptor in the minority of cancer types where it is present produces factors that inhibit cancer progression. The oral dosage of mifepristone for these studies have been mostly 200mg per day and a few patients were treated with 300mg per day.
Conclusion/Relevance
The efficacy of mifepristone needs to be confirmed in larger clinical trials. Related to the lack of need for production of membrane progesterone receptors or nuclear progesterone receptors in normal non-pregnant life, suppression of the progesterone receptor has little or no side effects. Progesterone receptor antagonists, such mifepristone, or perhaps even improved progesterone receptor antagonist versions, have the potential to provide a major anti-cancer therapy either alone or combined with other anti-cancer therapies.

Introduction

Patients with advanced cancers without any more treatment options may seek advice from various types of physicians including family physicians, internal medicine specialists, sub-specialists depending on the type of cancer (such as gastroenterologists, pulmonary specialists, etc.), oncologists, and palliative care/hospice specialists. Generally, at this stage the option would be hospice versus the referral to a tertiary oncology center hoping that they are aware of another approved treatment option not known to their present oncologist. Of course, another hope is that there is a new clinical trial drug in which the patient would qualify.

Alternatively, many patients would decide to undergo palliative care/hospice to end the suffering, not only from the cancer itself, but from the side effects of the anti-cancer therapy.

There is one other option and that is to turn to alternative medicine. To bring a new drug to market it generally costs the pharmaceutical company about 3 billion dollars. A good percentage of that total is spent on the payment for oncology departments to run clinical trials. Thus, without pharmaceutical support potential effective therapies may be available only as clinical case reports or small series.

Many times, the results of randomized controlled trials are published, or more likely with patients with cancer, a large series with comparisons to expectant results. However, it is not unusual for a different clinical trial from another oncology center reaching opposite conclusions. Subsequently to help decide which trial results should one believe to decide on a medical therapy, one may look for a meta-analysis combining the results of all clinical trials. However, based on the criteria of selection of what studies to include, frequently, meta-analyses reach opposite conclusions.

To complicate matters, with a 3-billion-dollar investment, pharmaceutical companies must handpick the patient most likely to succeed. Thus, patients with very advanced metastatic cancers that have progressed despite standard or experimental therapies are usually excluded from clinical trials.

Nevertheless, this group of patients not desirable for a clinical trial may be a good group to evaluate a potential therapy on a case-by-case basis. Even one case showing a good response may suggest to the patient/clinician the possibility that there still may be hope using an alternative therapy. Of course, they must still weigh the cost of that treatment and potential side effects.

Even more impressive for the potential benefits of an alternative ant-cancer therapy would be if there are multiple case reports about one treatment that can provide marked palliative benefits for a prolonged period of time. If that therapy was effective for not just some patients with a particular type of cancer (such as non-small cell lung cancer positive for the epidermal growth factor receptor representing only a small percentage of all non-small cell lung cancer showing extended life or palliation from tyrosine kinase inhibitors) but for most patients with that cancer, it would seem reasonable to at least try that alternative anti-cancer therapy. Even more impressive would be if that particular alternative anti-cancer therapy had shown benefit in case reports for multiple different types of advanced cancer especially if that benefit extended life over 5 years despite starting at a initial terminal stage. Even more credence to try that alternative therapy would be given if that drug has little or no side effects. Certainly, the alternative therapy would be worth trying if that drug could be given orally allowing the patient to avoid hospitalization, or visits to oncology centers to receive out patient infusions. The drug would certainly provide interest if the cost was as little as 60 dollars per month in some countries up to $1500 in some other countries compared to 50 to 70 thousand dollars per month which is the cost of the monoclonal antibody immunotherapy drugs.

The purpose of this manuscript is to review 25 years of human clinical experience with an oral agent taken once per day that fulfills all of the requirements listed above. This anecdotal experience has been presented without criticism for at least 20 years mostly at the American Association for Cancer Research. The anecdotal case reports have been published in major anti-cancer journals. Yet without the backing of large pharmaceutical companies, though the drug is commercially available even as a generic, its approved use is for another purpose not for treating cancer. Thus, the hope of this 25-year review of our clinical experience in treating patients with cancer with this therapy is that this information will be promulgated to not only the members of the European Society of Medicine but other physicians and scientists around the world who may find this summary interesting enough to try this therapy on their patients. Hopefully other clinicians will then share their experiences and/or stimulate the interest of other scientists now aware of these new concepts of immunoendocrine therapy and possibly even develop more efficacious anti-cancer therapies based on this model.

The link between reproductive and cancer immunology

The fetal placental unit and the malignant tumor share certain characteristics: rapid proliferation of cells, invasion into normal tissue, and avoidance of immune surveillance. It is simply amazing how a fetus with very strong foreign paternal antigens can proliferate in a very vascular area and not be rejected by the cellular immune system.

Though cancer cells have foreign onco-fetal antigens, they are much less antigenic than the embryonic cells, mesenchymal cells, and trophoblast cells of the fetus. The hope was to detect one pathway that is utilized by both the fetus and cancer cells that is needed to prevent immune rejection. It seemed logical to start with the fetal placental semi allograft to find a key immunomodulatory protein that is essential for both the fetal placental unit and malignant tumor to produce to allow them to escape immune surveillance. Thus, subsequently, the knowledge accrued could help to facilitate correcting infertility and preventing miscarriage. The hope would be to create methods to stimulate that protein in infertile women or women with a history of recurrent miscarriage. In contrast, for treating cancer, theoretically, one would search for finding a method to suppress such a protein, which could lead to an effective anti-cancer therapy.

Studies of reproductive immunology led to the discovery of an immunomodulatory protein (the progesterone induced blocking factor (PIBF)) that seemed to be essential in suppressing immune destruction of the fetal semi-allograft1,2. This led to the first proposed model of anti-cancer therapy by suppressing the production of this PIBF protein, which, similar to the fetus, may be used by cancer cells to evade immune surveillance also3. Some studies suggest that PIBF suppresses natural killer (NK) cell activity by inhibiting release of perforin granules and granzymes. Also, PIBF may suppress cytotoxic T cell activity by altering prostaglandin activity, thus causing a shift from TH-1 to TH-2 mediated activity thus decreasing cytotoxic T cell activity4,5.

After 1996, the date of our first publication concerning PIBF, more data accrued providing more insight as to how the PIBF protein helped the fetus to proliferate and invade normal tissue and evade immune surveillance. In 2003 the exact amino acid sequence of the PIBF protein was determined, which allowed the subsequent development of a pure monoclonal antibody against PIB6. Originally, the circulating gamma/delta T cell was considered the main source of PIBF expression. However, it was subsequently determined that it is also made by highly proliferating cells7. For the reproductive immunology model, PIBF was found to be made by the rapidly growing embryonic cells, mesenchymal cells, and trophoblast cells of the fetal place unit7. However, just as important, PIBF was also shown to be made by rapidly growing cancer cells7.

There is evidence that it is not the parent kDa protein that is immunosuppressive, but smaller molecular weight splice variants (e.g., 35kDa PIBF splice variants). Though the 35kDa splice variant can suppress cytotoxic activity of NK cells, macrophages, and cytotoxic T cells, the NK cell was considered to be the main cell that it suppressed since it is the predominant white blood cell found in the fetal placental microenvironment8,9. Thus, we suggested that in some way rapidly growing cancer cells may produce the 35 kDa splice variant of PIBF thus inhibiting cytotoxic activity of local NK cells10. Therefore, it would be logical to see if one inhibits local production of PIBF by rapidly growing cancer cells if this could suppress PIBF by malignant tumors and thus act as an anti-cancer therapy. In the years from 2006 to 2020 several pharmaceutical companies became interested in treating cancer by directing a monoclonal antibody against the key protein made by the normal cells that prevents autoimmune attack of normal tissue that seemed to also be made by many different malignant tumors. This protein is called the programmed death factor-1 (PD-1) and its ligand (PD-L1) that was needed for continued rapid proliferation, invasion into normal tissue and evasion of immune surveillance. Thus, a new direction in treating cancer was developing. Instead of cytotoxic chemotherapeutic agents that can kill rapidly growing cancer cells, but also rapidly growing normal cells leading to significant side effects and complications, or finding a specific chemical pathway needed for certain cancers to proliferate that was not needed for normal cells, but to find a key immunoprotective protein that can be inhibited by a monoclonal antibodies11.

Though our hope was that the basic science data would influence some pharmaceutical company to consider treating various cancers with a monoclonal antibody directed against PIBF, instead the research and development was aimed at immunotherapy against the programmed cell death factor –1 (PD-1) which is a protein present on cytotoxic T cells (and at least partially responsible for its cytotoxic activity) or its ligand called PD-L1 made by normal cells that helps to establish immune tolerance to normal tissues. The ligand acts as a key that can turn off the "motor" of the cytotoxic T cell by interacting with PD-1 present on the cytotoxic T cell. Thus, PD-1 is considered an immune check-point and monoclonal antibodies directed against either PD-1 or PD-L1 or earlier substrate proteins needed to make PD-1 e.g., CTLA-4 are known as immune check point inhibitors (ICIs). They have become a very important anti-cancer therapy12–14. Not only do normal cells make the PD-L1 to interact with the PD-1 on cytotoxic T cells to negate its cytotoxic activity, but so do many different types of cancers. By blocking the interaction of PD-L1 with PD-1 by a monoclonal antibody to either PD-1 or its ligand, this acts by "turning the motor back on" the cytotoxic T cells and thus subsequently cytotoxic activity is restored

Thus, around 2009 the first 2 ICIs (pembrolizumab and nivolumab) were approved as anti-cancer agents. Though they continue to be a very important anti-cancer therapy, eventually the cancer seems to find a way to become resistant to the various ICIs15,16.

Furthermore, because PD-L1 is made by normal tissue to induce immune tolerance, it is not surprising that these drugs may be associated with significant autoimmune attack of normal tissue causing autoimmune morbidities and even death as a side effect17,18.

In contrast, PIBF seems to be made in significant amounts only in the normal female post ovulation and during pregnancy. Thus, by suppressing this PIBF protein, if this was found to be another significant target for anti-cancer treatment, there may be little or no adverse side effects since its only known function is to allow the fetal placental unit to rapidly proliferate, invade normal tissue, and evade immune surveillance.

Whereas lower molecular weight splice variants of the 90kDa parent protein (35kDa) seem responsible for inhibition of immune surveillance, evidence suggests that it is the 90kDa parent protein that may not only be responsible for trophoblast invasion into normal tissue, but also cancer cells19,20.

Thus, if these aforementioned studies would have influenced pharmaceutical companies to develop a monoclonal antibody anti-cancer treatment inhibiting PIBF, it is not clear if directing it against the 90kDa protein would be sufficient to prevent the production of the 35KDa PIBF protein, or would there be more efficacy to target just the 35KDa protein, or would both be needed? However, since these aforementioned studies did not influence pharmaceutical companies to explore monoclonal antibody therapy against PIBF, the question arises: Could there be some other way to inhibit PIBF production by rapidly growing cancer cells? Could there be a drug already on the pharmaceutical market that could be re-purposed for treating cancer by suppressing PIBF production by the malignant tumor?

The role of progesterone receptor antagonists as an anti-cancer therapy

Many studies showed that at least one method to stimulate PIBF is exposure to progesterone21,22. Even males will produce significant amounts of PIBF when exposed to progesterone23.

It is logical to assume that since P can stimulate PIBF production, it must interact with a progesterone receptor (PR). Subsequently, the P and PR complex following nuclear transcription will translate the message. There are 2 different types of PRs: nuclear PRs (nPR) and cell membrane PRs (mPR). The classical nPR is a member of the steroid hormone super family of nuclear receptors and are ligand-activated transcription factors24,25. Thus, the interaction of P and the classical nPR is a genomic process in which the signaling pathway involves P binding to nPRs in the cytoplasm. This leads to a conformational change with dissociation of heat shock proteins, dimerization, translocation to the nucleus, and binding to hormone responsive elements in target genes24,25. Typically, genomic processes resulting in the initiation of transcriptional activity is a slow process. The histologic changes occurring during the luteal phase most likely result from the interaction of P and the classical nPR.

Membrane PRs (mPRs) belong to the P and adipo Q receptor (PAQR) family26. Interaction of P and mPRs, in contrast to nPRs, lead to rapid signaling in seconds to minutes27. Membrane PR expression is widely distributed in several organs including the reproductive structures, brain, kidney, colon, lungs, and cells of the immune system28,29.

Thus, if one considers that there is a similarity between the fetal placental unit and cancer, and with the knowledge that it only takes one pill of 200mg oral mifepristone to abort a normal pregnancy, perhaps using a progesterone receptor inhibitor would be an alternative option to suppress PIBF to treat cancer rather than a monoclonal antibody to suppress PIBF30.

Against the use of a PR antagonist was the fact that there had been some previous clinical trials with mifepristone that were not that impressive. There was a pervading thought that if a nuclear hormone receptor was present in a malignant tumor, e.g., the estrogen receptor, it may be needed for continued growth and spread of the cancer. Indeed, there was some benefit found by treating certain cancers with the presence of the nuclear estrogen receptors with selective estrogen receptor modulators e.g., tamoxifen, in inhibiting tumor recurrence or metastases with nuclear estrogen receptor positive breast cancer. However, treating cancers with nPRs positive cancers with mifepristone treatment was disappointing for breast cancer31–33.

Similarly, treatment with mifepristone for ovarian epithelial cancer and advanced or recurrent endometrial carcinoma or low-grade stromal cancers positive for the nPR were also disappointing34,35.

Thus, one theoretical possible explanation for the lack of success in treating nPR positive cancers with a PR antagonists is that despite the PR antagonist effectively suppressing PIBF, this immunomodulatory protein does not play a vital role in cancer progression. A second possibility is that PIBF is an essential protein that allows cancer progression. However, PR antagonists fail to adequately suppress PIBF. Possibly the tumor can make some substance that inhibits PR antagonists from suppressing PIBF. For example, mifepristone does not lower serum PIBF levels secreted by circulating gamma/delta T cells in the presence of P36.

However, another possibility is that the PR antagonist mifepristone does suppress PIBF, but the production of PIBF involving rapidly acting non-genomic mPRs rather than the slow genomic nPR is the target. Possibly, the nPR is responsible for the secretion of other proteins that inhibit cancer progression. Thus, mifepristone may be suppressing not only PIBF by inhibiting mPR activity but suppressing factors that normally inhibit cancer progression via the nPR. Thus, one may be inhibiting a protein that the cancer cells make that allows cancer progression at the same time suppressing factors that limit cancer progression. Possibly the best efficacy of using PR antagonists for treating cancers that are positive for the nPR is to only use PR antagonists when the cancer loses the nPR (usually when it becomes more aggressive) or for the majority of cancers that are devoid of the classical nPR. In support of this third hypothesis is the fact that there are data showing a better prognosis when the nPR is present, and increased aggressiveness when the nPR is lost37–41.

Effect of mifepristone on suppressing PIBF experience from human cancer cell lines with mifepristone

Because of strong anti-abortion sentiments from certain influential groups one could not easily obtain mifepristone in the United States or other countries even if the purpose was not terminating a pregnancy, but treating cancer! In the United States it was required to obtain a compassionate use investigational new drug (IND) approval on a case-by-case basis from the Food and Drug Administration (FDA). In general, it was necessary to prove that the patient had very advanced (usually terminal) cancer without any other treatment options.

Of course, the FDA would first want to see some evidence of efficacy, not merely theory. Thus, the next step needed would be to perform controlled animal studies. Our intention was to use mice bred for a high rate of spontaneous cancers rather than chemically induced cancers. However, these specially bred mice were expensive (approximately $150.00 per mouse). Therefore, before investing so much money for the murine studies, it seemed prudent to first prove that PR antagonists can suppress PIBF. Based on the mediocre benefit in human cancers positive for the nPR, it seemed the best cancer cell line to evaluate PIBF production and subsequent suppression of PIBF production with mifepristone would be a cancer that is devoid of the classical nPR.

We actually made a deal with a physician knowledgeable in immunology who was in menopause who wanted us to use our technology of up-regulating down-regulated FSH receptors to induce ovulation and then freeze the embryos formed for future transfer of these embryos to a gestational carrier. Our consult resulted in learning that her father, a Ph.D. was studying protein synthesis of many different types of human leukemia cell lines for many years.

We made a trade for free egg retrievals every time we could create an egg in exchange for their collaboration on evaluating if these leukemia cell lines produce PIBF. Furthermore, the study would determine if adding P to the medium could up regulate mRNA for PIBF and to stimulate production of the PIBF protein itself. Even more important would be to evaluate whether mifepristone could suppress expression of both mRNA and the PIBF protein from these human leukemia cell lines.

In fact, these data did show that without any stimulus there was more mRNA dedicated to making PIBF by far compared to any other protein that Dr. Srivastava studied over 30 years. P did increase both mRNA for PIBF and PIBF protein itself. Most importantly, mifepristone significantly reduced PIBF mRNA, and the PIBF protein itself42.

From a human-interest standpoint, the FSH receptor up regulation technique was able to create mature follicles in many cycles over a 5-year time period resulting in 3 healthy children (the last one from an embryo derived from this menopausal woman which was frozen over 20 years43,44.

Evaluating the efficacy of mifepristone treatment for mice with a high prevalence of cancers that are not associated with the presence of the classical nPR

Mifepristone was gavaged into mice with a high rate of spontaneous cancers with a dosage on a weight basis that would be equivalent to treating humans with a daily dosage of 200mg/day. The controls were gavaged daily with olive oil which was the vehicle in which the mifepristone was dissolved.

The mice were housed in a vivarium and the animal keeper who determined their body conditioning scores (the equivalent of quality of life in humans) was blinded as to the treated group versus the controls. The gavaging was performed by our own staff. We followed the rules established by anti-vivisectionists which required the mice to be sacrificed at 1 year no matter how healthy they appeared.

The treated mice were found to have a considerable better quality of life and longevity in the 4 types of cancer we evaluated: leukemia, lung, prostate, and testicular45–47. These cancers were chosen because of being devoid of the classical nPR. In humans, sometimes prostate cancer may be positive for the nPR.

As an example of the efficacy of mifepristone as an anti-cancer therapy, A/J mice with spontaneous lung cancer had a survival rate of 57.6% vs 27% for controls. Obviously, some of the deaths were not cancer related. Even more impressive than survival statistics, the mean number of sick days, as objectively judged by body conditioning scores by a non-biased blinded observer, was 11.6 days for mifepristone treated mice vs 57.6 days for the controls46.

The efficacy of mifepristone in humans with very advanced metastatic cancer with no more treatment options

Following institutional review board approval for treating human patients with advanced cancers of all types with 200mg per day oral mifepristone, we were able to obtain a compassionate use IND for this group of patients from the FDA. Since our practice is predominately reproductive and medical endocrinology and internal medicine, and gynecology, the recruitment of these patients were generally obtained from our patient population who did not seek our services for oncologic purposes who subsequently developed cancer and which became very advanced. Sometimes the patient sources were relatives of our patients or referrals from the relatives of our own staff.

We have published a case report on every patient that we have treated unless they died within one week of treatment from their very advanced malignant state or they stopped mifepristone after a short time period because they qualified for another treatment modality or clinical trial without allowing us to determine if mifepristone was effective or not. Initially, there was only one pharmaceutical company who supplied mifepristone (Danco, Inc.) who would send it to the Feminist Majority Group. That group would then send the mifepristone tablets to the patients. Neither Danco Inc. nor the Feminist Majority Group would release the mifepristone 200mg per day without a compassionate use IND from the FDA. Some patients who were interested in treatment died before we attained FDA approval which was frequently delayed by weeks.

Though the first patient we treated for advanced cancer was thymic epithelial cell carcinoma, the first case report that we published concerned a 61-year-old woman with very widely metastatic adenocarcinoma of the transverse colon48. The multiple metastatic lesions involved her liver, peritoneum, ovaries, and uterus, and she had marked ascites. Her case was also described in a compendium of cases of advanced cancer that provided a follow-up of these cases treated with mifepristone until their death and other details49.

We had not published the case reports of other patients treated prior to the colon cancer because we were not sure they would be sufficiently convincing to oncologists. However, this case of colon cancer left little doubt in our minds about the potential efficacy of treating cancer with PR antagonists48,49.

The patient was advised by her oncology team that she would probably not live longer than 1 more month and she was in so much pain and marked fatigue that she was bed-ridden. Within 5 weeks after starting mifepristone she was pain free and her energy returned to normal. Her ascites had disappeared. Her carcinoma embryonic anliges (CEA) level that had been markedly elevated was now in the normal range of 1.9mg/ml.

Initially her oncologist advised against chemotherapy when she was in this advanced state. However, now seeing that she was feeling perfectly normal, the oncologist decided to add to the mifepristone chemotherapy with bevacizumab and 5- Fluorouracil. She did not have any side effects from mifepristone but had mild side effects from the chemotherapy but decided that they were tolerable. Thus, she stayed on both of these chemotherapy drugs plus the mifepristone.

The patient was referred by the lead author's cousin. Thus, her monitoring and evaluation was continued by the oncologist. She was still feeling great at 18 months, and her CT scan showed no more metastatic lesions or growth of any of them and many totally regressed or were smaller, but several were still present despite the combination of mifepristone and chemotherapy. However, she still did not have any ascites, and her serum CEA was only 1.3ng/ml. Though her chemotherapy was paid for by her insurance company the mifepristone was considered an off-label use so she had to pay for it out of pocket. With a 50% reduced price though the Feminist Majority Group she paid about $600 per month. To save money she asked the oncologist if he/she thought that she could take the mifepristone every other day. The oncologist thought that would not have any consequences since she was also taking her chemotherapy.

Three months after reducing the dosage of mifepristone by 50%, but not reducing the dosage of chemotherapy, the metastatic lesions started to grow again. Though she was still feeling well, the oncologist advised her to stop both the chemotherapy and the mifepristone. She died 3 months later (24 months from starting mifepristone). This author was not aware of the fact that she reduced the mifepristone dosage or that she stopped the drug altogether. Why she did not seek the author's opinion is very confusing. Admittedly, we had turned her management and further evaluation to the oncologist. Of course, had she asked for our opinion we would have advised her to stay on mifepristone daily rather than every other day and definitely not stop it because new lesions were now appearing.

There are a lot of inferences that one can derive from this case. She restored a good quality of life in a short time period, and yet at that time there was no evidence of any tumor regression or progression. This makes one wonder if these mPR induced immunomodulatory proteins are the main factors contributing to the marked asthenia and pain seen in patients with cancer. Thus, this inhibition of these factors by PR antagonists can quickly restore quality of life.

The oncologist, despite her clinical improvement with mifepristone, decided to now add chemotherapy that was considered earlier likely to be ineffective. Fortunately for her, the side effects from the chemotherapy were tolerable, but did impact her quality of life to some degree. Following many more years of experience since this case from 20 years ago, at least with very advanced, standard treatment resistant cancer, the main criteria of efficacy should be quality of life and longevity of life rather than tumor regression or total remission.

More experience shows that the response to mifepristone seen in patients with other types of advanced cancers is typical i.e., marked improvement in quality of life, and either mild to moderate extension of life (depending on how advanced is the cancer at the time of mifepristone treatment. Five-year survival rates are not uncommon with death frequently from other age-related events e.g., myocardial infraction or stroke or co-morbidities e.g., chronic obstructive pulmonary disease. When death occurred from the cancer progression it usually was following stopping the mifepristone either because of lack of finances or at the advice of the oncologist who wanted to enroll the patient in a new clinical trial. With lack of experience with this drug, many oncologists are used to seeing complete or partial remission from a given anti-cancer therapy. However, with disease progression or recurrence they advise stopping because the cancer usually rapidly progresses at this time. This is usually not the case with PR antagonists. Increased size of some lesions are generally not associated with rapid progression, and the patient can usually continue to have an extended good quality life. Interestingly, and unfortunately when at least starting out with very advanced cancer, which is being kept in check by mifepristone, stopping the drug even for just a week or two is usually associated with rapid spread of the cancer and death within 2-3 weeks.

One 68-year-old man had stage IV non-small lung cancer (NSCLC) with brain metastasis. He was referred by an oncologist from New York because there were no more treatment options. He was aware of our use of mifepristone by his daughter, who was one of our OB-GYN residents who because of her interest in reproductive endocrinology/infertility, she attended not only the obligatory rotation but took extra clinical and research electives on our service.

At this time, we had accumulated enough anecdotal clinical response experience with mifepristone therapy for advanced cancer that we applied for and were approved by the FDA for an investigator-initiated study and was approved to treat 40 patients with stage IV NSCLC that had progressed despite a minimum of 2 rounds of chemotherapy or immunotherapy. They also approved 2 principal investigators. Since Corcept Inc was willing to provide the 300mg dosage gratis, we chose to treat with 300mg oral mifepristone daily.

After one month of mifepristone he stated that he had marked improvement in his symptoms of dyspnea on exertion, cough, and marked fatigue49–51. He stated that this was the best he had felt in 10 years. After 2.5 years when there had been no evidence of recurrence of brain lesions, and only partial remission of the other metastatic legions, (but no new ones and no growth of primary tumor), one of the previous metastatic lesions increased in size slightly. His oncologist advised him to stop the study, and he would treat him with nivolumab since the drug had now been approved for lung cancer even if the PD-1/PD-L1 marker was negative. The oncologist thought that once there is any growth, the treatment is no longer effective.

Because based on the requirements of the study we evaluated him monthly, he asked my opinion and I advised him not to stop. His quality of life remained very good for the next 3 years despite the fact that the one lesion continued to enlarge slightly. He died 5.5 years after starting mifepristone. He actually did not die from his cancer per se but as a complication of COVID51. Interestingly, despite his marked clinical improvement, his oncologist has never referred another patient despite the fact that he is still in active practice in oncology. I know from his daughter, who is a reproductive endocrinologist, that he, her father, is not using mifepristone for his other patients. He was in private practice but sold it to a university oncology center, and he now works for them. Their policy may be not to prescribe off-label use of drugs unless part of a clinical trial

Actually, the very first patient we treated with mifepristone with thymic epithelial cell cancer had a similar story in that she saw very marked improvement in her fatigue, dyspnea on exertion, and cough. This considerable clinical improvement lasted the entire 2 years that she was taking the mifepristone. However, despite no new metastatic lesions and no growth of the pre-existing lesions, nevertheless, her oncologist, a radiation therapist, decided to try a second course of radiation therapy that previously had not provided any clinical or radiographic improvement. She died of pulmonary fibrosis as a complication of the second course of radiation therapy49,52. According to her husband, who was a member of a lay group called the thymic epithelial cell cancer group, she lived the longest of anyone at that time with thymic epithelial cell cancer once this cancer became metastatic. We did not verify the veracity of that statement. This patient was started with mifepristone 25 years ago. I am not sure if there are any new treatments extending life better. She had been previously in a clinical trial with octreotide, but it was stopped because of lack of observed efficacy.

Only one patient, an 80-year-old woman, appeared to have a complete remission based on radiographic evidence. She had rapidly advancing small cell lung carcinoma (SCLC) with marked fatigue, shortness of breath, and cough, with multiple bilateral lung lesions. At initial presentation her pO2 was 72mm Hg and her serum sodium was 118 mmol/L. She was advised by the oncologist that she would probably die within 2 weeks and thus recommended hospice. She was not a candidate for any anti-cancer therapy. After 1 month of oral mifepristone 200mg/day she noted marked improvement in energy and no shortness of breath. Her CT scan was now completely normal. Her pO2 increased to 99mmHg without oxygen supplementation. Her syndrome of inappropriate anti-diuretic hormone was eradicated with a serum sodium now completely normal at 145 mmol/L49,53. The patient died at age 85 with a myocardial infarction while her SCLC remained in complete remission49.

Another case of SCLC was a 59-year-old man who failed to halt rapid progression with chemotherapy and immunotherapy. He had a very poor quality of life before starting mifepristone. Two months after starting 200mg/day mifepristone, his CT scan showed partial remission. However, clinically he was feeling much better and was able to resume strenuous sports, e.g., skiing and scuba diving. After 1 year still feeling very well, one of the primary lesions had shown slight growth. The oncologist opted to stop mifepristone and try immunotherapy with a new monoclonal antibody directed against PD-L1. His cancer rapidly progressed and he died. The patient had been cautioned that stopping the drug would probably result in rapid progression and death. we asked a friend of his why did he not at least try to resume the drug and he said that once the new drug was started and the mifepristone stopped, he was not in a proper mental state to make that decision49,51,54. Actually, the aforementioned patients with NSCLC and SCLC were summarized in a 6 patient review that despite being in a moribund state with no more treatment options and estimated to be within 3 months of death; we reported a good quality 66.7% overall 5-year survival51,55.

We generally strongly advise patients that the drug does not "cure" the cancer but creates a stable disease with marked improvement in quality of life. We greatly emphasize the fact that even a 2-week cessation in the daily usage will usually result in rapid progression and death. One 46-year-old man with metastatic fibroblastic osteosarcoma had no more treatment options and was advised that death will probably occur within 3 months. The author met on a cruise. His wife was a nurse. They decided to be treated with mifepristone.

He had since initiating the drug marked improved quality of life but had occasional slow growth of metastatic lesions that caused pain and led to either local resection or radiotherapy. He was still feeling good after 5 years, but one of the slow growing lesions was giving him some mild pain again. His oncologist advised him that there was a clinical trial that he could enter for a new drug for treating fibroblastic osteosarcoma, but he would have to stop the mifepristone. The oncologist told him that if after 1 month there was no shrinking in the size of the slow growing lesion, he could stop the study and resume the mifepristone. His wife remembered my admonition and begged him not to stop the mifepristone. He did not listen and he died 2 weeks later not from an adverse event from the new drug, but from very rapid cancer spread49,56.

Mifepristone has been found to be highly effective for certain very aggressive cancers that normally do not respond to chemotherapy or immunotherapy. Two moribund patients with stage IV pancreatic cancer, one already on hospice, and one advised to enter hospice had a great response to mifepristone. A 57-year-old male that was probably within 1-2 weeks of dying resumed a perfectly normal pain-free life with good energy within 1 month of therapy. Unfortunately, though he wanted to resume his job, it was no longer available. The $600 per month was a financial hardship for his children. Thus, at 9.5 months he decided to stop the drug and died 2 weeks later49,57.

An 83-year-old moribund women with stage IV pancreatic cancer had marked relief of her pain, marked improved energy, and return of her appetite after starting mifepristone. Her oncologist had previously advised hospice before mifepristone therapy. After 2 months she slipped in the shower and broke her nose and ribs and was unconscious for an unknown period of time. She was hospitalized and the hospital administrators refused to allow her to take the mifepristone because it was an off-label use. She died 3 weeks later from rapidly advancing cancer. She never resumed the drug58.

In contrast another cancer that is usually resistant to chemotherapy or immunotherapy when advanced was found in an 85-year-old male with end stage congestive heart failure. With the finding of this additional co-morbidity of advanced cholangiocarcinoma, the physicians advised hospice. However, he still wanted to live so chose to start mifepristone (He was the father-in-law of one of our nurses). He had a good quality year with no progression and actual partial regression of the cholangiocarcinoma. He died not from the cancer but from heart failure59.

Mifepristone has been tried on 2 patients with stage IV breast cancer, one of whom was initially positive for the estrogen and progesterone nuclear receptor and one with the biopsy made only when she initially presented with stage IV breast cancers with extensive brain metastases. The tumor in the latter patient was ER but not PR positive. Both patients were considered moribund. One patient was the daughter of one of our successful infertility patients, and this first patient was diagnosed with breast cancer at age 31. We had frozen her embryos before starting chemotherapy and hormonal therapy with tamoxifen. When it was evident that the cancer had metastasized, she had a baby by the transfer of an embryo to her twin sister (who was also a previous infertility patient in our clinic). Thus, we had been in contact with her for several years and kept advising mifepristone as various other anti-cancer therapies did not provide very much clinical benefit. However, her oncologist refused treatment citing previous unsatisfactory experience in the literature with mifepristone treatment of breast cancer. When the last anti-cancer drug, alpelisib, showed no benefit, he strongly advised hospice to stop the suffering she had over the last 6 years. However, to spend just a little more time with her baby and other loved ones she now tried the mifepristone. She very quickly had a marked improvement in her quality of life stating that she had not felt this good in years. Shockingly, despite her clinical improvement, her oncologist convinced her to enter hospice because her tumor markers were increasing! She listened and died 2 weeks later60.

A second patient, a former employee, showed considerable objective improvement of quality of life after taking mifepristone. However, she died 6 months later not because the cancer progressed, but related to a brain metastatic lesion rupturing a cerebral blood vessel causing a lethal cerebrovascular accident61.

We have reported palliative benefits for other types of cancers. Though we have only treated one case of glioblastoma multiforme grade IV. We mention him here not because of marked longevity from treatment but his returning to a normal cognitive state. However, this was the first evidence that mifepristone can cross the blood brain barrier and possibly treat other primary brain cancers or metastatic brain cancer62. This 43-year-old male was semi-comatose and paralyzed from the neck down. Within 2 weeks he regained full consciousness and had normal mentation. Though his energy had markedly improved, he still had some difficulty in breathing and swallowing. After 3 months, with no evidence for the clinical deterioration he thanked us for the extra time but elected to stop the drug. He died within one week49,62.

Other cancers that we have treated include a case of transitional cell carcinoma of the renal pelvis. He only lived for 2 months. However, he was considered to have only a week to live49,52. It is not the length of life that is impressive about this case. His oncologist called to ask about the mifepristone because this oncologist, from a very well-known medical center in mid-west United States, said that they had never seen any previous cancer of any kind that had such rapid aggression with multiple new metastatic lesions despite anti-cancer therapy every time they did a CT scan at 3 months intervals. When he survived 6 weeks, the oncology team out of curiosity performed another CT scan. For the first time not only were there no more new lesions, but many disappeared and many decreased in size49,52.

He was in a semi-comatose state partly because of the asthenia of the cancer but also partly from high dosage opiates that were not that effective in reducing his pain. Within a few days the patient's energy markedly improved. Even more impressive, his pain markedly dissipated allowing him to discontinue the opiates and just take occasional acetaminophen. Since his very wealthy wife was so pleased to have this last 2 months of good quality life with her husband with normal mentation, for a number of years she paid for the drug for several of the subsequent patients with cancer that we treated who had insufficient funds to pay for the drug49–52. The oncologist said that this patient was a timebomb and that the tumor was wrapped around many arteries and he probably bled to death from a ruptured artery. Other cancers showing some palliative benefit from treating patients with very advanced cancer include fibrous histiocytoma, urothelial cancer, and prostate cancer52,63,64.

The case of prostate cancer deserves some mention. An 83-year-old male had end-stage metastatic prostate cancer. His life expectancy was not expected to be beyond one month. He had severe skeletal pain. His main wish was to just be well enough to be able to say good-bye to his large family and friends from various geographic locations, but with dignity. Unfortunately, we would not be able to acquire a compassionate use IND in enough time or even guarantee that the FDA would grant approval. Thus, we treated him with another PR antagonist ulipristal. Similar to mifepristone, in a short period of time he regained a good amount of energy and marked relief of pain. He had a good quality of life for one month and said goodbye to his family and friends. However, he decided to stop therapy because the cost was similar to mifepristone. At age 83, he assumed he would not live much longer anyhow. He wanted to leave his wife with some money after his death rather than leaving her broke paying for his medication64.

Future Directions

The purpose of writing a review on treating cancer with a PR antagonist e.g., mifepristone, is to hopefully influence a physician or clinic that has a decent population of patients with cancer to evaluate the efficacy of mifepristone therapy in a study with sufficient power to be convincing. Unfortunately, though we have had consultations with several patients with advanced cancer, most have decided not to be treated with mifepristone. Possibly this is related to the fact that the cost per pill has doubled to $42 per pill and is not covered by insurance companies because is it off label (the price in India and China may be only one to two dollars per day). Insurance companies do not have to pay for the drug because it is off label. What they do not seem to realize that a cost of $15,000 per year pales in comparison to 500 thousand to 1 million dollars per year from ICIs.

The controversy about mifepristone is that it is approved to terminate a pregnancy. Some states e.g., Florida and Texas have even banned shipping the drug to doctors in those states. At present, the drug no longer requires a compassionate use IND from the FDA. Thus, it is legal to be shipped from the manufacturer. There is still a ban on supplying pharmacies, and the drug can only be shipped to the physician. It is ludicrous to think that an oncologist, or for that matter an internal medicine specialist or family doctor, cannot be trusted to pretend it is for a patient for cancer but then us it as an abortifacient. The safety of the drug for daily use has been established. It costs far less money for a drug company to repurpose a drug, then get a new drug onto the pharmaceutical market65. Yet the manufacturers of the generic mifepristone do not seem interested in trying to get the drug repurposed.

We have published suggestions as to how a large pharmaceutical company could create an even more effective anti-cancer therapy. There are other PR influenced immunomodulatory proteins, e.g., the progesterone receptor membrane component one (PGRMC-1) protein66–70. There is evidence that PGRMC-1can increase cancer aggressiveness also71–74.

Mifepristone is not a pure PR antagonist. A better term would be a PR modulator. In higher dosages mifepristone suppresses both PIBF and PGRMC-1. However, in lower dosages, similar to that achieved by daily dosage of 200 to 300 mg, mifepristone suppresses PIBF but increases PGRMC-175. Perhaps PIBF suppresses tumor metastasis, but possibly PGRMC-1 is more involved in local tumor growth75. This could explain the common findings with mifepristone treatment with effective inhibition of metastatic spread, but somehow allowing some slow growth of the primary lesions. Thus, from a pharmaceutical standpoint, development of a new drug could be to develop a pure PR antagonist that does not also block the glucocorticoid receptor (as does mifepristone) to allow a dosage high enough that it will suppress both PIBF and PGRMC-176,77.

Another option would be to develop a monoclonal antibody directed against PIBF, which possibly could be more effective than a PR antagonist. If in fact mifepristone blocks a protein, i.e., PIBF, that leads to metastases, but also stimulates a protein that increases local tumor aggression (PGRMC-1), one could conclude that PIBF would be the more important immunosuppressive protein to inhibit than PGRMC-1. If, in fact mifepristone blocks an immunomodulatory protein whose function is to promote metastasis but at the same time stimulate PGRMC-1, whose function may be to promote local growth it would appear based on observed clinical improvement PIBF is the more important immunosuppressive protein to negate. Thus, possibly a monoclonal antibody could inhibit PIBF but at least not increase PGRMC-1.

One could hypothesize that factors made by the nPR when present may inhibit tumor secretion of PIBF, PGRMC-1 or both or even some other immunomodulatory protein not detected as yet77.

Based on our 25 years of the human experience, if a large clinical trial is conducted to evaluate the efficacy of mifepristone or another PR antagonist, we have 2 main suggestions: 1) Choose a cancer devoid of the classical nPR and 2) Use as the primary outcome quality of life and longevity with tumor regression or remission as secondary parameters.

Patients quickly feel so much better from a pain and fatigue standpoint before there is any demonstratable regression in their lesions. This suggests that at least part of the morbidity with advanced cancer is not always from the lesions compressing nerves, arteries, etc. or other organs but could be related to the effects of the PR related immunomodulatory proteins that causes the cancer to progress. Thus, by suppressing PIBF and possible other PR immunomodulatory protein, this may contribute to marked improvement of quality of life.

To date, almost all of the anecdotal reports have involved very advanced cancer states. The question arises if larger studies confirm the efficacy of PR antagonists for very advanced cases, could they also have benefit for less advanced cases?

The United States FDA only gave us permission to treat one case that was less advanced who had multifocal renal cell carcinoma with mifepristone rather than a bilateral nephrectomy which was the standard of care at that time. There were no anticancer drugs at that time for this type of cancer. Thus, he had a laparoscopic hemi nephrectomy of his right kidney removing the largest lesions but no surgery on his left kidney with 3 lesions present. After 11 years, the 3 lesions remained present but did not change in size. No new lesions appeared in either the half right kidney or the whole left kidney. His diabetes mellites eventually caused end stage renal failure, so a bilateral nephrectomy was performed after 11 years of mifepristone treatment. He had a kidney transplant. We recommended to stay on mifepristone because of the possibility of distant metastases. However, related to cost, he decided to stop for now but resume it if any metastatic lesions appeared. Ten years after stopping mifepristone at age 81 he is still in good health and there has been no development of any metastatic lesions49. With a change in FDA policy a compassionate use IND is no longer required, and we can use mifepristone today even at an earlier stage.

Thus, if clinical trials show efficacy in sufficiently powered studies perhaps other studies could evaluate whether taking mifepristone, or some other PR antagonist, or a monoclonal antibody directed against PIBF and/or PGRMC-1 could inhibit recurrence after surgical resection or radiotherapy.

Conclusion

It is hoped that with this presentation of the concept that immunosuppressive proteins made by membrane progesterone receptors are required for most cancers to metastasize, and that the use of a PR antagonist can suppress these proteins leading to tumor regression and longevity will stimulate interest in some physicians to try this therapy in patients with advanced cancers with no more treatment options. Hopefully they will then share their experience either corroborating our data or refuting our data. Perhaps if they corroborate our data, they will find other cancers that we have not treated as yet showing similar benefits and share that data with the readers. Hopefully, this report will stimulate interest leading to the development of even better PR antagonists than mifepristone. Most of all it is hoped that this manuscript will lead some physicians to try it and enable some patients suffering from this dreaded disease to have many more months or years of an extended life.

There are so many drugs already on the pharmaceutical market that can be used off-label to treat other medical conditions. If they are still under patent health insurance company would likely deny an off-label use. However, if that drug is available as a generic then frequently the cost may be less than the co-pay for the brand drug. Thus, if health providers can be educated that if reimbursement for the far less expensive generic drug that may be even more effective than the far more expensive FDA approved anti-cancer drug, possibly they could be influenced to pay for the off-label drug.

Though there are 2 generic companies that can manufacture mifepristone in addition to Danco Inc which manufactures the brand name under Mifeprex®. In some countries the generic is the same price as the brand where the drug costs $42 per pill. It is intended to be taken as only one pill to terminate a pregnancy. With the need to take it daily, perhaps, even in those countries, e.g., the United States, charging the higher price per pill, a pharmaceutical company could be influenced to significantly reduce the price and still make a profit because of the increase in volume of sales related to the need for daily use in a large number of patients. Alternatively, even without creating an improved PR antagonist which would take many years to become available and cost possibly 3 billion dollars, it is far less expensive to re-purpose a drug for another use77. Furthermore, the time to market would also be immensely shortened.

Since we have found both 200 and 300mg daily dosages to be equally effective perhaps the re-purposed mifepristone could be 250mg per day. Mifepristone has passed safety requirements with the 300mg dosage which is approved for the hyperglycemia of Cushing’s syndrome because in high dosages (even above 300mg) since mifepristone also blocks the glucocorticoid receptor in higher dosages. In lower dosages mifepristone has provided marked palliative benefits and extension of life in patients who have failed with extremely expensive immune checkpoint inhibitors and tyrosine kinase inhibitors51,78,79. Thus, it is reasonable, if affordable, to even offer mifepristone to patients with advanced cancer even before some approved therapies especially if the standard therapies will have significant potential side effects, hospitalization for administration or side effects, and immense expense based on the type or lack of insurance coverage for standard anti-cancer agents. Certainly, it would seem reasonable to offer mifepristone as an anti-cancer agent with known human anecdotal benefits as opposed to a clinical trial for a drug without known efficacy and unknown risk of serious morbidity or mortality from side effects.

Declarations

Conflict of Interest
The author has no conflicts of interest to declare.
Acknowledgement
We would like to acknowledge Megan McDonald O'Neil for her valuable assistance with the preparation of this manuscript, including editing, formatting, and typing of the manuscript. Her support and attention to detail contributed to the completion and refinement of the final manuscript. We also acknowledger Carrie Wilson who helped manage some of our clinical trials.

References

  1. Check JH, Szekeres-Bartho J, O’Shaughnessy A. Progesterone induced blocking factor seen in pregnancy lymphocytes soon after implantation. Am J Reprod Immunol. 1996;5:277-280.
  2. Check JH, Arwitz M, Gross J, et al. Evidence that the expression of progesterone-induced blocking factor by maternal t-lymphocytes is positively correlated with conception. Am J Reprod Immunol.1997;38:6-8.
  3. Check JH, Nazari P, Goldberg J, Yuen W, Angotti D. A model for potential tumor immunotherapy based on knowledge of immune mechanisms responsible for spontaneous abortion. Med Hypotheses. 2001;57(3):337-343. DOI: 10.1054/mehy.2001.1333.
  4. Szekeres-Bartho J, Kinsky R, Chaouat G. The effect of the progesterone induced immunologic blocking factor on NK mediated resorption. Am J Reprod Immunol. 1990;24:105-107.
  5. Szekeres-Bartho J, Wegmann T. A progesterone-dependent immunomodulatory protein alters the Th1Th2 balance. J Reprod Immunol. 1996;31:81-95.
  6. Polgar B, Kispal G, Lachmann M, et al. Molecular cloning and immunologic characterization of a novel cDNA coding for progesterone-induced blocking factor. J Immunol. 2003;171:5956-5963.
  7. Lachman M, Gelbmann D, Kalman E, et al. PIBF (progesterone induced blocking factor) is overexpressed in highly proliferating cells and associated with the centrosome. Int J Cancer. 2004;112:51-60.
  8. Check JH, Aly J, Chang E. Improving the chance of successful implantation – part I – embryo attachment to the endometrium and adequate trophoblast invasion. Clin Exp Obstet Gynecol. 2016;43(6):787-791.
  9. Check JH, Aly J. Improving the chance of successful implantation – part 2 – Circumventing immune rejection and the fetal semi-allograft. Clin Exp Obstet Gynecol. 2018;45(1):9-13.
  10. Check JH, SanSoucie L, Chern J, Amadi N, Srivastava M, Larece K. Evidence that progesterone receptor antagonists may help in the treatment of a variety of cancers by locally suppressing natural killer cell activity. Clin Exp Obstet Gynecol. 2007;34:207-211.
  11. Check JH, Nkwenkwa-Ganpo N. The role of membrane progesterone receptor associated proteins in gynecological and reproductive disorders, and cancers: an editor’s historical perspective Part 3: The role of mPRs and immunomodulatory proteins in development of benign and malignant tumors and endometriosis. J Sex Health Reprod Med. 2026; 2(2):1-10. DOI: doi.org/10.61440/JSHRM.2026.v2.3.
  12. Fife BT, Bluestone JA. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev. 2008; 224: 166-82. DOI:10.1111/j.1600-065X.2008.00662.x.
  13. Smith-Garvin JE, Koretzky GA, Jordan MS. T cell activation. Annu Rev Immunol. 2009; 27:591-619. DOI 10.1146/annurev.immunol.021908.132706.
  14. Jhunjhunwala S, Hammer C, Delamarre L. Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion. Nat Rev Cancer. 2021; (5):298-312. DOI: 10.1038/s41568-021-00339-z.
  15. Pavelescu LA, Enache RM, Roşu OA, Profir M, Creţoiu SM, Gaspar BS. Predictive Biomarkers and Resistance Mechanisms of Checkpoint Inhibitors in Malignant Solid Tumors. Int J Mol Sci. 2024;25(17):9659. DOI:10.3390/ijms25179659.
  16. Pandey MR, Ernstoff MS. Mechanism of resistance to immune checkpoint inhibitors. Cancer Drug Resist. 2019; 2(2):178-188. DOI:10.20517/cdr.2018.015.
  17. Zoghbi M, Burk KJ, Haroun E, Saade M, Carreras MTC. Immune checkpoint inhibitor-induced diarrhea and colitis: an overview. Support Care Cancer. 2024; 32(10):680. DOI: 10.1007/s00520-024-08889-2.
  18. Liu K, Wang YH, Luo N, Gong J, Wang J, Chen B. Treatment-related gastrointestinal adverse events of nivolumab plus ipilimumab in randomized clinical trials: a systematic review and meta-analysis. Future Oncol. 2023; 19(27):1865-1875. DOI:10.2217/fon-2022-0615.
  19. Miko E, Halasz M, Jeericevic-Mulac B, et al. Progesterone induced blocking factor (PIBF) and trophoblast invasiveness. J Reprod Immunol. 2011;90:50-57.
  20. Halasz M, Polgar B, Berta G, et al. Progesterone-induced blocking factor differentially regulates trophoblast and tumor invasion by altering matrix metalloproteinase activity. Cell Mol Life Sci. 2013;70:4617-4630.
  21. Check JH, Szekeres-Bartho J, Nazari P, Katz Y, Check ML. A corpus luteum is not a prerequisite for the expression of progesterone induced blocking factor by T-lymphocytes a week after implantation. J Assist Reprod Genet. 2001;18(11):603-607.
  22. Cohen RA, Check JH, Dougherty MP. Evidence that exposure to progesterone alone is a sufficient stimulus to cause a precipitous rise in the immunomodulatory protein the progesterone induced blocking factor (PIBF). J Assist Reprod Genet. 2016;33:6221-229.
  23. Check JH, DiAntonio A, Check DL, Dougherty MP, DiAntonio G. A study to determine if estrogen (E) is needed to induce de novo progesterone (P) receptors on gamma/delta T-cells as evidenced by determining the degree of rise of progesterone induced blocking factor (PIBF) following P exposure in males. Clin Exp Obstet Gynecol. 2020; 47(3):419-420.
  24. Proietti C, Salatino M, Rosemblit C, et al. Progestins induce transcriptional activation of signal transducer and activator of transcription 3 (Stat3) via a Jak- and Src-dependent mechanism in breast cancer cells. Mol Cell Biol. 2005;25(12):4826–4840.
  25. Tsai SY, Carlstedt-Duke J, Weigel NL, et al. Molecular interactions of steroid hormone receptor with its enhancer element: evidence for receptor dimer formation. Cell.1988; 55(2):361–369.
  26. Valadez-Cosmes P, Germán-Castelán L, González-Arenas A, et al. Expression and hormonal regulation of membrane progesterone receptors in human astrocytoma cells. J Steroid Biochem Mol Biol.2015;154:176–185.
  27. Faivre EJ, Daniel AR, Hillard CJ, Lange CA. Progesterone receptor rapid signaling mediates serine 345 phosphorylation and tethering to specificity protein 1 transcription factors. Mol Endocrinol. 2008;22(4):823–837.
  28. Zhu Y, Bond J, Thomas P. Identification, classification, and partial characterization of genes in humans and other vertebrates homologous to a fish membrane progestin receptor. Proc Natl Acad Sci U S A. 2003;100(5):2237–2242.
  29. Pang Y, Dong J, Thomas P. Characterization, neurosteroid binding and brain distribution of human membrane progesterone receptors d and {epsilon} (mPRd and mPR{epsilon}) and mPRd involvement in neurosteroid inhibition of apoptosis. Endocrinology. 2013;154(1):283–295.
  30. Mahajan DK, London SN. Mifepristone (RU486): A review. Fertil Steril.1997;68:967-976.
  31. Ramieu G, Maudelonde T, Ulmann A, et al. The antiprogestin RU486 in advanced breast cancer preliminary clinical trial. Bulletin Du Cancer. 1987;74:455-461.
  32. Kligin JG, Setyono-Han B, Foekens JA. Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer. Steroids. 2000;65:825-530
  33. Perrault D, Eisenhauer EA, Pritchard KI, et al. Phase II study of the progesterone antagonist mifepristone in patients with untreated metastatic breast carcinoma: a national cancer institute of canada clinical trials group study. J Clin Oncol. 1996; 14(10):2709–2712.
  34. Rocereto TF, Brady WE, Shahin MS, et al. A phase II evaluation of mifepristone in the treatment of recurrent or persistent epithelial ovarian, fallopian, or primary peritoneal cancer: a gynecologic oncology group story. Gynecol Oncol. 2010;116(3):332-334.
  35. Ramondetta LM, Johnson AJ, Sun CC, et al. Phase 2 trial of mifepristone (RU-486) in advanced or recurrent endometrial adenocarcinoma or low-grade endometrial stromal sarcoma. Cancer. 2009;115(9):1867–1874.
  36. Check JH, DiAntonio G, DiAntonio A, Duroseau M. The progesterone receptor antagonist mifepristone does not lower serum progesterone induced blocking factor (PIBF) in the presence of progesterone. Clin Exp Obstet Gynecol. 2016;43(2):189-191.
  37. Bardou VJ, Arpino G, Elledge RM, Osborne CK and Clark GM. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol. 2003;21(10):1973-1979. DOI: 10.1200/JCO.2003.09.099
  38. Pichon MF, Pallud C, Brunet M and Milgrom E. Relationship of presence of progesterone receptors to prognosis in early breast cancer. Cancer Res. 1980;40(9):3357-3360.
  39. Dowsett M, Cuzick J, Wale C, Howell T, Houghton J and Baum M. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: a hypothesis generating study. J Clin Oncol. 2005;23(30):7512-7517. DOI: 10.1200/JCO.2005.01.4829
  40. Zhang Y, Zhao D, Gong C, Zhang F, He J, Zhang W, et al. Prognostic role of hormone receptors in endometrial cancer: a systematic review and meta-analysis. World J Surg Oncol. 2015;13:208. DOI: 10.1186/s12957-015-0619-1
  41. Zhao D, Zhang F, Zhang W, He J, Zhao Y and Sun J. Prognostic role of hormone receptors in ovarian cancer: a systematic review and meta-analysis. Int J Gynecol Cancer. 2013;23(1):25-33. DOI: 10.1097/IGC.0b013e3182788466
  42. Srivastava MD, Thomas A, Srivastava BI, Check JH. Expression and modulation of progesterone induced blocking factor (PIBF) and innate immune factors in human leukemia cell lines by progesterone and mifepristone. Leuk Lymphoma. 2007;48(8):1610-1617.
  43. Srivastava P, Srivastava M. Check JH. Protocol Details and Outcome Analysis of 5 Years of Continuous Infertility Treatment in A Patient with Premature Ovarian Insufficiency/Failure and Complex Crohn's Disease Utilizing Her Own Oocytes and outcome of 3 pregnancies. J Sex Health Reprod Med. 2026;2(2):1-6. DOI: doi.org/10.61440/JSHRM.2026.v2.45
  44. Check JH, Srivastava. How temporarily reversing menopause to achieve 3 children led to a novel highly effective anti-cancer therapy- an editorial and case report. J Sex Health Reprod Med. 2026;2(2):1-9. DOI: 10.61440/JSHRM.2026.v2.46
  45. Check JH, Sansoucie L, Chern J, Amadi N, Katz Y. Mifepristone treatment improves length and quality of survival of mice with spontaneous leukemia. Anticancer Res. 2009;29(8):2977-2980.
  46. Check JH, Sansoucie L, Chern J, Dix E. Mifepristone treatment improves length and quality of survival of mice with spontaneous lung cancer. Anticancer Res. 2010;30(1):119-122.
  47. Check JH, Dix E, Wilson C, Check D. Progesterone receptor antagonist therapy has therapeutic potential even in cancer restricted to males as evidenced from murine testicular and prostate cancer studies. Anticancer Res. 2010;30:4921-4924.
  48. Check JH, Dix E, Sansoucie L, Check D. Mifepristone may halt progression of extensively metastatic human adenocarcinoma of the colon – case report. Anticancer Res. 2009;29(5):1611-1613
  49. Check JH. Novel immunoendocrine therapy of advanced cancers of all types opens a new medical field for clinical and research endocrinologists. Am J Biomed Sci Res. 2024;23(1):86-98.
  50. Check DL, Check JH. Significant palliative benefits of single agent mifepristone for advanced lung cancer that previously failed standard therapy. Med Clin Sci. 2019;1(2):1-5.
  51. Check JH, Check DL, Wilson C. Good quality (66.7%) 5-year overall survival in terminal lung cancer patients treated with mifepristone. Anticancer Res. 202; 45(12):5785-5798. DOI: 10.21873/anticanres.17911.
  52. Check JH, Dix E, Cohen R, Check D, Wilson C. Efficacy of the progesterone receptor antagonist mifepristone for palliative therapy of patients with a variety of advanced cancer types. Anticancer Res. 2010;30:623-628.
  53. Check JH, Check DL, Dougherty MP. Progesterone receptor antagonists – a novel treatment for severe hyponatremia from the endocrine paraneoplastic syndrome. J Endocrinol Res. 2021;3:40-43.
  54. Check JH, Check DL, Poretta T, Srivastava M, Check E. Significant palliative benefits following therapy with mifepristone for advanced treatment resistant small cell lung cancer. Anticancer Res. 2024;44:659-664.
  55. Check JH, Poretta T, Check D, Srivastava M. Lung Cancer - Standard therapy and the use of a novel, highly effective, well tolerated, treatment with progesterone receptor modulators. Anticancer Res. 2023;43(3):951-965.
  56. Check JH, Check D, Poretta T, Wilson C. Palliative benefits of oral mifepristone for the treatment of metastatic fibroblastic osteosarcoma. Anticancer Res. 2021;41:2111-2115.
  57. Check JH, Check D, Srivastava MD, Poretta T, Aikins JK. Treatment with mifepristone allows a patient with end-stage pancreatic cancer in hospice on a morphine drip to restore a decent quality of life. Anticancer Res. 2020;40:6997-7001.
  58. Check JH, DiAntonio A. Though pancreatic cancer may be resistant to immunotherapy from immune check-point inhibitors, it may be sensitive to blocking production of immunoprotective proteins unique to pregnancy. IgMin Res. 2026;4(4):110-115. DOI: 10.61927/igmin338.
  59. Check JH. Evidence that the use of progesterone receptor modulators/antagonists can provide palliative benefits for a moribund patient with cholangiocarcinoma. Int J Med Pharm Res. 2025; 6(2):162-164.
  60. Check D, Check JH, Wilson C. Alpelisib combined with low dose mifepristone for treating advanced breast cancer may cause hypokalemia even when this complication does not occur from single use of the anticancer agents. Cancer Sci Res. 2020;3:1-4.
  61. Check JH, Ganpo NN. Marked palliative benefits seen with treatment of very advanced breast cancer with the progesterone receptor modulator mifepristone. Anticancer Res. 2026; 46(2):1153-1165. DOI: 10.21873/anticanres.18018.
  62. Check JH, Wilson C, Cohen R, Sarumi M. Evidence that mifepristone, a progesterone receptor antagonist can cross the blood brain barrier and provide palliative benefits for glioblastoma multiforme grade IV. Anticancer Res. 2014;34:2385-2388.
  63. Check JH, Check DL, Neumann BA. Palliative benefits of treatment of advanced urothelial cancer with progesterone receptor antagonist. J Biomed J Sci Tech Res. 2024;57(2):49092-49095.
  64. Check JH, Webman D. The progesterone receptor antagonist ulipristal markedly improved quality of life in a patient with end-stage prostate cancer. Int J Clin Case Reports and Rev. 2025;27(3):866.
  65. Check JH, Check DL. Progesterone and Glucocorticoid Receptor Modulator Mifepristone (RU-486) as Treatment for Advanced Cancers. In: Saxena SK, editor. Drug Repurposing – Molecular Aspects and Therapeutic Applications. London: IntechOpen; 2020. DOI:10.5772/intechopen.93545.
  66. Mifsud W and Bateman A. Membrane-bound progesterone receptors contain a cytochrome b5-like ligand-binding domain. Genome Biol. 2002;3(12):0068.
  67. Cahill MA, Jazayeri JA, Catalano SM, Toyokuni S, Kovacevic Z, Richardson DR. The emerging role of progesterone receptor membrane component 1 (PGRMC1) in cancer biology. Biochim Biophys Acta, 2016;1866(2):339-349. DOI: 10.1016/j.bbcan.2016.07.004
  68. Ahmed IS, Rohe HJ, Twist KE, Craven RJ. Pgrmc1 (progesterone receptor membrane component 1) associates with epidermal growth factor receptor and regulates erlotinib sensitivity. J Biol Chem. 2010; 285(32):24775-24782. DOI:10.1074/jbc.M110.134585.
  69. Kabe Y, Nakane T, Koike I, Yamamoto T, Sugiura Y, Harada E, et al. Haem-dependent dimerization of PGRMC1/Sigma-2 receptor facilitates cancer proliferation and chemoresistance. Nat Commun. 2016;7:11030. DOI: 10.1038/ncomms11030
  70. Peluso JJ, Pappalardo A, Losel R, Wehling M. Expression and function of PAIRBP1 within gonadotropin-primed immature rat ovaries: PAIRBP1 regulation of granulosa and luteal cell viability. Biol Reprod. 2005;73(2):261-270. DOI: 10.1095/biolreprod.105.041061
  71. Hampton KK, Stewart R, Napier D, Claudio PP, Craven RJ. PGRMC1 elevation in multiple cancers and essential role in stem cell survival. Adv Lung Cancer. 2015;4(3):37-45. DOI: 10.4236/alc.2015.43006
  72. Ruan X, Zhang Y, Mueck AO, Willibald M, Seeger H, Fehm T, et al. Increased expression of progesterone receptor membrane component 1 is associated with aggressive phenotype and poor prognosis in ER-positive and negative breast cancer. Menopause. 2017; 24(2):203-209. DOI: 10.1097/GME.0000000000000739.
  73. Peluso JJ, Liu X, Saunders MM, Claffey KP, Phoenix K. Regulation of ovarian cancer cell viability and sensitivity to cisplatin by progesterone receptor membrane component-1. J Clin Endocrinol Metab. 2008;93(5):1592-1599. DOI: 10.1210/jc.2007-2771
  74. Tsai HW, Ho CL, Cheng SW, Lin YJ, Chen CC, Cheng PN, et al. Progesterone receptor membrane component 1 as a potential prognostic biomarker for hepatocellular carcinoma. World J Gastroenterol. 2018;24(10):1152-1166. DOI: 10.3748/wjg.v24.i10.1152
  75. Ponikwicka-Tyszko D, Chrusciel M, Stelmaszewska J, Bernaczyk P, Chrusciel P, Sztachelska M, et al. Molecular mechanisms underlying mifepristone’s agonistic action on ovarian cancer progression. EBioMedicine. 2019; 47:170- 183. DOI: 10.1016/j.ebiom.2019.08.035
  76. Check JH, Check D. Therapy aimed to suppress the production of the immunosuppressive protein progesterone induced blocking factor (PIBF) may provide palliation and/or increased longevity for patients with a variety of different advanced cancers – A review. Anticancer Res. 2019;39:3365-3372.
  77. Check JH, Check D, Neumann B. Future directions to explore to develop ideal anti-cancer progesterone receptor modulators. Cancer Sci Res. 2023;6(1)1-8.
  78. Check DL, Check JH, Poretta T, Aikins J, Wilson C. Prolonged high-quality life in patients with non-small cell lung cancer treated with mifepristone who advanced despite osimertinib. Cancer Sci Res. 2020;3(2):1-5.
  79. Check JH, Check D, Poretta T. Mifepristone extends both length and quality of life in a patient with advanced non-small cell lung cancer that has progressed despite chemotherapy and a check-point inhibitor. Anticancer Res. 2019;39:1923-1926.

Article information

Authors

  • Jerome H. CheckCooper Institute for Reproductive Hormonal Disorders, Mt Laurel, NJ, USA; Department of Obstetrics/Gynecology, Division Head of Reproductive Endocrinology and Infertility at Cooper Medical School of Rowan University Camden, NJ, USA
  • Diane L. Check

How to cite

Check, J. H., Check, D. L., 2026. Clinical benefits of progesterone receptor antagonists in advanced cancers devoid of nuclear progesterone receptors: 25 years’ experience. Medical Research Archives, [online] 14(10). https://doi.org/10.18103/mra.2026.0662

Record

Journal
Medical Research Archives
Section
Review Articles
Published
31 October 2026
ISSN
2375-1924
Downloads
47

Copyright and licence

Published by the European Society of Medicine under a Creative Commons Attribution 4.0 International licence (CC BY 4.0), which permits unrestricted use, distribution and reproduction in any medium, provided the original authors and source are credited.